Ascletis hits 5-week high on new drug applications for obesity treatment
06/07/2026 06:34
BUZZ-Ascletis hits 5-week high on new drug applications for obesity treatment ** Shares of Ascletis Pharma 1672.HK climb 11.7% in their fifth straight session of gains to HK$12.89, highest point since June 1
** Stock on course for its biggest one-day pct rise since March 26, if current gains hold
** Pharmaceutical products developer says it has submitted two Investigational New Drug applications to the U.S. Food and Drug Administration (FDA) for its ASC36 and ASC36_35 FDC for obesity treatment
** YTD, Hong Kong stock up 3.9%, Hang Seng Biotech Index .HSBIO up 0.5%
(Reporting by Donny Kwok)
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management